Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer

JHOP - June 2022 Vol 12, No 3 - FDA Oncology Update
Download PDF

On May 4, 2022, the FDA granted a regular full approval for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) for adults with unresectable or metastatic HER2-positive breast cancer who had previously received an anti-HER2 regimen in the metastatic or the neoadjuvant or adjuvant setting whose disease recurred during or within 6 months of completing therapy, based on the confirmatory DESTINY-Breast03 clinical trial.

“Enhertu has demonstrated significant progression-free survival in the earlier metastatic setting, potentially establishing it as a new standard of care in previously treated patients with HER2-positive metastatic breast cancer. Today’s approval is an important milestone for the clinical community as we will now be able to offer Enhertu to these patients earlier in their treatment,” said Erika Hamilton, MD, Director of the Breast Cancer and Gynecological Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, in a press release.

This regular approval was based on the results of the confirmatory clinical trial DESTINY-Breast03 conducted after the December 2019 FDA accelerated approval for fam-trastuzumab deruxtecan for adults with unresectable or metastatic HER2-positive breast cancer who have received ≥2 anti-HER2 regimens in the metastatic setting.

The DESTINY-Breast03 study was a multicenter, open-label, randomized clinical trial of 524 patients with HER2-positive, unresectable, and/or metastatic breast cancer who had received trastuzumab and taxane therapy for metastatic disease or whose disease recurred during or within 6 months of completing neoadjuvant or adjuvant therapy. Patients were randomized (1:1) to intravenous fam-trastuzumab deruxtecan or to ado-trastuzumab emtansine every 3 weeks, until disease progression or unacceptable adverse events.

The main efficacy outcome measure was progression-free survival (PFS). Key secondary end points were overall survival (OS) and confirmed objective response rate (ORR). The median PFS was not reached (95% confidence interval [CI], 18.5-not estimable) in the fam-trastuzumab deruxtecan arm and was 6.8 months (95% CI, 5.6-8.2) in the ado-trastuzumab emtansine arm. The hazard ratio was 0.28 (95% CI, 0.22-0.37; P <.0001). At the time of the PFS analysis, 16% of patients had died and the OS was immature. The ORR was 82.7% (95% CI, 77.4-87.2) and 36.1% (95% CI, 30.0-42.5), respectively.

The most common (incidence >30%) adverse reactions with fam-trastuzumab deruxtecan were nausea, fatigue, vomiting, alopecia, constipation, anemia, and musculoskeletal pain. Serious adverse reactions in >1% of patients with this drug were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. The prescribing information of fam-trastuzumab deruxtecan includes a warning about the risk for interstitial lung disease and embryo-fetal toxicity.

Related Items
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Tibsovo Received a New Indication, in Combination with Onureg, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.